- The total Type 1 Gaucher Disease market exceeds $1.6 billion dollars
- All 5 approved Type 1 drugs continue to show year over year growth
- The indication supports multiple drugs
- Premium pricing is preserved with average annual drug cost per patient exceeding $360,000
- Pricing remains strong even as new drugs are introduced
- Early mover advantage
LifeSci Capital Equity Research Analysis of Orphan Drug Market February 4, 2016